Optimizing benefit/risk in oncology: Review of post-marketing dose optimization and reflections on the road ahead
-
Published:2023-02
Issue:
Volume:182
Page:103913
-
ISSN:1040-8428
-
Container-title:Critical Reviews in Oncology/Hematology
-
language:en
-
Short-container-title:Critical Reviews in Oncology/Hematology
Author:
Soltantabar PoonehORCID,
Lon Hoi-Kei,
Parivar Kourosh,
Wang Diane D.,
Elmeliegy MohamedORCID
Subject
Oncology,Hematology
Reference72 articles.
1. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial;Ascierto;Lancet Oncol.,2017
2. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial;Assouline;Lancet Haematol.,2016
3. Population pharmacokinetics of durvalumab in cancer patients and association with longitudinal biomarkers of disease status;Baverel;Clin. Pharmacol. Ther.,2018
4. Safety and dose modification for patients receiving niraparib;Berek;Ann. Oncol.,2018
5. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma;Berenson;Blood,2016
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献